Filter

201 - 210 of 319 Results

  • Which States are Hitting the COVID-19 Vaccine Tipping Point?

    News Release

    As of April 19, COVID-19 vaccine eligibility opened up to adults in all states, leaving many to wonder when supply will surpass vaccine demand. A recent brief examined when COVID-19 vaccine supply might outstrip demand in the U.S. nationally, estimating that the U.S. will reach this point within a few weeks.

  • Supply vs Demand: Which States are Reaching their COVID-19 Vaccine Tipping Points?

    Policy Watch

    This analysis examines overall COVID-19 vaccination levels and how the rate of vaccinations over the last week has changed at state-level and national level. There is significant variability by state in how many adults in the US have been vaccinated with at least one dose. Most states are also seeing a decline in the pace of vaccinations, indicating that they may be approaching the point when vaccine supply exceeds demand.

  • Global COVID-19 Vaccine Equity: U.S. Policy Options and Actions to Date

    Issue Brief

    This brief examines U.S. policy options for helping expand global access to COVID-19 vaccines, focusing on four main areas: in-kind donations of vaccine doses, additional funding for global access mechanisms like COVAX, helping expand global vaccine manufacturing, and relaxing or waiving intellectual property protections on vaccine technologies. We summarize what the administration has done to date in these areas and policy issues related to each.

  • KFF COVID-19 Vaccine Monitor: What We’ve Learned

    Poll Finding

    This brief summarizes key findings and themes from the COVID-19 Vaccine Monitor project that is tracking the dynamic nature of the U.S. public’s attitudes and experiences with COVID-19 vaccination, and is based on more than 11,000 interviews conducted since December 2020.

  • Vaccine Monitor: What We’ve Learned

    News Release

    With nearly all states poised to allow anyone at least 16 years old to get a COVID-19 vaccine, this week’s announcement pausing the distribution of the Johnson & Johnson vaccine to investigate a rare side effect is raising questions about whether and how it will affect the public’s eagerness to get vaccinated.